Related Experiment Videos
Measurement of cdk4 kinase activity using an affinity peptide-tagging technology
J J Wu1, D R Yarwood, M A Sills
1Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ 07901, USA. jinzi.wu@phrma.novartis.com
Combinatorial Chemistry & High Throughput Screening
|March 7, 2000
Summary
A new homogeneous assay using affinity peptide-tagging technology enables rapid discovery of Cdk4 inhibitors. This robust method simplifies screening by eliminating separation steps, aiding cancer research.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Cyclin-dependent kinases (CDKs), including CDK4, regulate cell cycle progression.
- CDK4 misregulation is linked to various cancers, highlighting the need for targeted inhibitors.
- Developing efficient screening assays for CDK4 inhibitors is crucial for cancer therapy.
Purpose of the Study:
- To develop a novel homogeneous assay for rapid discovery of CDK4 inhibitors.
- To utilize affinity peptide-tagging technology for simplified kinase assays.
- To establish a robust and high-throughput screening method for CDK4 inhibitors.
Main Methods:
- Engineered a fusion protein (GST-Rb152-StrepTag) with a retinoblastoma protein domain and a StrepTag.
- Used the engineered protein as a substrate for in vitro CDK4 kinase assays.
- Employed scintillation proximity assay (SPA) with streptavidin-coated beads for signal detection.
Main Results:
- The homogeneous assay successfully detected CDK4 phosphorylation activity.
- Affinity peptide tagging eliminated the need for separation and wash steps, simplifying the assay.
- The assay demonstrated robustness and suitability for high-throughput screening.
Conclusions:
- Developed a simple, robust, and homogeneous assay for CDK4 inhibitor screening.
- Affinity peptide-tagging technology offers a generic platform for kinase and protein-interaction assays.
- This method accelerates the discovery of potential anti-cancer therapeutics targeting CDK4.